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Shiga toxin type 2 (Stx2), a toxin secreted by Shiga toxin-producing Escherichia coli (STEC), could be one of the causes of maternal
and fetal morbimortality not yet investigated. In this study, we examined the effects of Stx2 in rats in the early stage of pregnancy.
Sprague-Dawley pregnant rats were intraperitoneally (i.p.) injected with sublethal doses of Stx2, 0.25 and 0.5 ng Stx2/g of body
weight (bwt), at day 8 of gestation (early postimplantation period of gestation). Maternal weight loss and food and water intake
were analyzed after Stx2 injection. Another group of rats were euthanized and uteri were collected at different times to evaluate
fetal status. Immunolocalization of Stx2 in uterus and maternal kidneys was analyzed by immunohistochemistry. The presence of
Stx2 receptor (globotriaosylceramide, Gb3) in the uteroplacental unit was observed by thin layer chromatography (TLC). Sublethal
doses of Stx2 in rats caused maternal weight loss and pregnancy loss. Stx2 and Gb3 receptor were localized in decidual tissues. Stx2
was also immunolocalized in renal tissues. Our results demonstrate that Stx2 leads to pregnancy loss and maternal morbidity in
rats in the early stage of pregnancy.This study highlights the possibility of human pregnancy loss andmaternal morbidity mediated
by Stx2.
1. Introduction
Maternal bacterial and viral infections during pregnancy
are associated with an increased incidence of fetal death,
congenital malformations, placental abruption, premature
rupture of membranes, and prematurity in humans and
animals [1]. Spontaneous miscarriage is the most common
adverse pregnancy outcome in humans and occurs in 15–
20% of all recognized pregnancies. Early pregnancy loss
is a common complication of human pregnancy and the
causes are often unknown and unstudied. The causes for a
spontaneous miscarriage are diverse and comprise genetic,
endocrinologic, anatomic, immunologic, or microbiologic
aspects [2]. Although miscarriage represents the most com-
mon complication in pregnancy and as such has been
thoroughly investigated, the causes of miscarriages are still
unexplained.
In the majority of cases [3], it is well known that the
pregnant state is associated with increased sensitivity to
endotoxin in renal and uterine circulation [4] and maternal
infection could cause abortion and preterm labour in women
[5]. Infections are accepted as a cause of late fetal demise and
could be responsible for early fetal losses as well [3].
Shiga toxin-producing Escherichia coli (STEC) are gas-
trointestinal bacteria whose infection can cause diarrhea
and hemorrhagic colitis. The systemic complication of STEC
infection is known as hemolytic uremic syndrome (HUS),
caused principally by the effects of Shiga toxin (Stx) in target
organs like kidney and brain. STEC infection is mostly seen
in young children including neonates [6, 7] although the
outbreak in 2011 in central Europe caused by Stx2-producing
STEC affected more adults than children, and women were
overrepresented [8–10]. STEC have a zoonotic origin and
they can be transmitted directly or indirectly from animals
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to humans. STEC are present in the intestinal tract of healthy
cattle, and transmission occurs not only by consumption
of undercooked ground beef, manure contaminated water,
vegetables, and fruit, and unpasteurized milk, but also by
direct contact from person to person [11]. After the inges-
tion of bacteria, STEC colonize the human intestine where
Stx is released and crosses the intestinal mucosal barrier.
Then, toxin circulates in the bloodstream and reaches its
target organs, mainly kidney and brain [12]. Stx has an
AB
5
molecular configuration where an enzymatically active
monomeric A subunit is noncovalently associated with a
pentamer of B subunit which is responsible for binding
to globotriaosylceramide (Gb3) (this receptor can be also
named CD77 or P
𝑘
blood group antigen) receptor [13].
Gb3 is located on the plasma membrane of target cells,
particularly endothelial cells present in kidneys, brain, and
other organs [14, 15]. Binding of Stx to Gb3 is the primary
determinant of its cytotoxic effects and results in toxin inter-
nalization and cell killing by inhibition of protein synthesis
and induction of apoptosis [16]. To our knowledge, there
are no reports of Stx2 effects during human pregnancy or
described complications in the early pregnancy associated
to STEC infection. However, several cases of hemolytic ure-
mic syndrome (HUS) after STEC infections in postpartum
women and neonate have been reported [6, 17–19]. Also
STEC, serotype O15:Krvc383, was diagnosed as the putative
cause of placentitis and late-gestation abortion in ewes [20].
The hypothesis is that early pregnancy can be affected by Stx2
through a direct effect in the uteroplacental unit. This event
could trigger complications or pregnancy loss. The purpose
of the present study was to examine the cytotoxic effects of
Stx2 in rats in the early stage of pregnancy after the event
of implantation. We propose that the systemic circulation of
Stx2 in the maternal vessels can affect the highly irrigated
uteroplacental unit and induce fetal and placental responses
associated with fetoplacental injury, leading to abortion
or pregnancy complications. The rationale for this study
is to evaluate the possibility of Stx2-mediated pregnancy
complications not previously considered and to direct further
attention to the role of soluble products of microorganisms
in the pathogenesis of abnormal gestation and pregnancy
complications.
2. Materials and Methods
2.1. Drugs and Chemicals. Purified Stx2 was purchased from
Phoenix Laboratory, TuftsMedical Center, Boston,MA,USA,
and it was checked for lipopolysaccharide (LPS) contamina-
tion by Limulus amoebocyte lysate assay (Biowhittaker Inc.,
MD,USA). Toxin was diluted with sterile phosphate-buffered
saline (PBS) before injection. Stx2 contained <10 pg LPS/ng
of pure Stx2. Gb3 standard was purchased from Matreya
(Pleasant Gap, PA, USA).
2.2. Animals. Timed pregnant rats were obtained mating
male and virgin female Sprague-Dawley rats (200–280 g;
2-3 months of age), acquired from the Animal Facility
of the School of Pharmacy and Biochemistry. Mating was
performed placing female rats in the cages of the male rats
from the same strain for several days. Day 1 of gestation was
determined when sperm was observed in the vaginal smear.
The animals received food and water ad libitum and were
housed under controlled conditions of light (12 h light; 12 h
dark) and temperature (23–25∘C). This study was carried out
in strict accordance with the recommendations detailed in
the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. Protocols were approved by
the Committee for the Care and Use of Laboratory Animals
of the University of Buenos Aires (CICUAL, Permit Number
2954/10 and 1494/2013). Three to six animals were used in
each experimental group. The experiments were repeated at
least twice.
2.3. Evaluation of Maternal Status. In order to examine the
effects of Stx2 on maternal status, pregnant rats on day 8 of
gestation (gd 8; day of delivery = 22-23 days) were randomly
divided into three groups of 4 animals each. This experiment
was repeated twice. One group was injected with a single
dose of 0.25 ng Stx2/g bwt, and the other group was treated
with a single dose of 0.5 ng Stx2/g bwt. Control rats were
injected with the same volume (1𝜇L/g bwt) of PBS. Pregnant
rats were individually housed, weighted, and checked for
water (mL) and food intake (g) every 24 h, until 9 days
after injection. Rats were followed until delivery to evaluate
delivery time. Signs of illness like piloerection, inactivity, and
vaginal bleeding were analyzed. Data of weight are presented
as Δweight (body weight at n day after injection-body weight
at 0 days after injection).
2.4. Evaluation of Fetal Status. After the evaluation of the
maternal status and progression of pregnancy, other groups
of rats of 3–6 animals each were injected with both doses of
Stx2 and PBS. Rats were sacrificed at 10 days after injection to
evaluate fetal status and the number of resorptions.Uteri were
removed and total fetal resorptions were macroscopically
evaluated. The experiment was repeated twice.
2.5. Gross Evaluation of the Uteroplacental Unit. For gross
evaluation of the fetal status after injection of both Stx2 doses
and PBS, groups of 3–6 animals each were sacrificed at 2, 4,
and 6 days after injection. Uteri were removed and the status
of the uteroplacental units was macroscopically evaluated.
Maternal kidneys and uteri were then formalin fixed for
histological evaluation. The experiment was repeated twice.
2.6. Histology. Uteroplacental units and maternal kidneys
from rats at 6 days after injection were fixed for 48 h
with formalin 10% in PBS 0.1M (pH 7.4). Two or three
uteroplacental units from every uterus (groups of 3–6 animals
each)were randomly dissected, dehydrated, and embedded in
paraffin. Sections of 5 𝜇m were made by a microtome (Leica
RM 2125, Wetzlar, Germany) and mounted on 2% silane
coated slides. The sections were stained with hematoxylin
and eosin (H&E) and observed by light microscopy (Nikon
Eclipse 200, NY, USA).
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2.7. Stx2 Immunohistochemistry. For Stx2 detection in mater-
nal kidney and uteroplacental units, animals injected with
0.5 ng/g bwt (total bodyweight) and controls were euthanized
after 6 h of treatment and finally formalin fixed for immuno-
histochemical studies.
Briefly, tissues were fixed with formalin 10% in PBS at
room temperature. The samples were then dehydrated and
embedded in paraffin. Tissue sections of 5 𝜇m thickness were
deparaffinized and hydrated, and subsequently endogenous





in PBS for 20min and rinsed with PBS. Later, the slides
were blocked with a 5% solution of dry milk in PBS in
a humidity chamber at room temperature for 90min to
prevent nonspecific protein binding. Sections were incubated
overnight at 4∘C with the mouse monoclonal antibody 2E11
(1 : 20; 12.5 𝜇g/mL) (kindly provided by Dr. Roxane M. F.
Piazza) against the A-subunit of Stx2 [21]. Sections were
then washed with PBS and incubated for 90min at room
temperature with a rabbit anti-mouse (Sigma-Aldrich Co.,
1 : 100) conjugated with peroxidase enzyme. Finally, slides
were incubated with 3,3󸀠-diaminobenzidine (DAB, Sigma-




, counterstained, dehydrated, and
mounted for observation. An isotype control was performed
with a mouse monoclonal anti-BrdU, dilution 1 : 20 (clone
DU33 #B 2531, Sigma, St. Louis,MO,USA),where no staining
was detected, not in decidua nor in the kidney (data not
shown). This assay was repeated at least twice.
2.8. Gb3 Determination. To assess whether Stx2 could bind
to decidua and uterus from pregnant rats at 8 days of ges-
tation, Gb3 presence in uterus and decidua was investigated
by thin layer chromatography (TLC). Neutral glycolipids
from decidua and uterus from rats of 8 days of gestation
were extracted according to the method of Bligh and Dyer
with minor modifications [22]. Briefly, 100mg of tissue was
weighted and homogenized on ice with an Ultra-Turrax
homogenizer with 0.8mL of HES buffer (10mM HEPES
KOH, 0.1mMof EDTA, and 250mMof sucrose).ThreemL of
chloroform :methanol 2 : 1 v/v was added to the homogenate,
vortexed for 30 s, and incubated on ice for 15min. Two mL
of chloroform : water 1 : 1 v/v was added to the tube and
centrifuged at 3000 rpm for 5min to separate phases. The
bottom phase was recovered and evaporated to dryness. One
mL of methanol and 0.1mL of 1.0M NaOH were added to
the dried residue and incubated at 37∘C overnight. Two mL
of chloroform and 0.5mL of water were added to the tube,
vortexed for 30 s, and centrifuged for 5min at 3000 rpm.
The lower phase corresponding to the neutral glycolipids was
brought to dryness.The residue was then suspended in 40 𝜇L
of chloroform: methanol 2 : 1 v/v and applied to the bottom
of the silica TLC plate (Merck Quı´mica Argentina). The
chromatographywas developed in a glass tank with amixture
of chloroform :methanol : water (60 : 35 : 8). A purified Gb3
standard (Matreya, Pleasant Gap, PA, USA) was also added
to the plate for comparison. After the solvent front reaches
the top of the plate, the gel matrix was air-dried and treated
with a solution of orcinol (50mg orcinol, 10mL of sulfuric
acid, and 39.5mL of water) to visualize the glycolipids.
Table 1: Effect of Stx2 on fetal status at 10 days after injection.





Control 10 13 ± 1 1 ± 1
0.25 ng/g bwt 6 4 ± 2∗ 8 ± 2∗
0.5 ng/g bwt 12 1 ± 1∗∗ 13 ± 1∗∗
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus control.
2.9. Creatinine Determination. For creatinine determination,
blood was collected by cardiac puncture of CO
2
anesthetized
rats injected with 0.5 ng Stx2/g bwt and PBS at 2, 4, and 6
days after injection (groups of 3–6 animals each). Plasma
creatinine concentration was determined using a commercial
kit (Wiener Lab, Argentina) according to the manufacturer’s
recommendations. The experiment was repeated twice.
2.10. Statistical Analysis. Statistical analysis was performed
using the Graph Pad Prism Software 5.0 (San Diego, CA,
USA). ANOVA for repeated measures was used to calculate
differences between groups in weight and food and water
intake and Tukey’s multiple comparisons test was used
as a posteriori test. Differences in the number of fetuses
and fetal resorptions were analyzed by Kruskal-Wallis test,
using Dunn’s multiple comparisons test as a posteriori test.
Differences in plasma creatinine concentration and delivery
of pups between Stx2-treated rats and controls were analyzed
by Mann-Whitney test. Statistical significance was set at 𝑃 <
0.05.
3. Results
3.1. Progression of Pregnancy in Rats Treated with Stx2. Doses
of 0.25 and 0.5 ng Stx2/g bwt i.p. injected into pregnant
rats caused signs of illness like piloerection and inactivity
from 2 days after injection until 7-8 days after injection.
Furthermore, a progressive decrease of food intake until day
7 after injection was observed (Figure 1(a)) with a consequent
fall of weight compared to controls (Figure 1(b)). Seven-eight
days after injection, rats gradually recovered appetite and
weight, although they did not reach theweight corresponding
to the time of pregnancy. All rats injected with 0.25 and
0.5 ng Stx2/g bwt showed vaginal bleeding on days 6–10
after injection. Controls gradually gained weight as expected
(Figure 1(b)). There were no differences in water intake in
Stx2-treated rats compared with their controls (Figure 1(c)).
Rats treated with the dose of 0.5 ng Stx2/g did not deliver any
pups, while a few rats treated with the dose of 0.25 ng Stx2/g
delivered some normal pups at term 6 ± 2 versus control
13 ± 2 (𝑃 < 0.05, 𝑛 = 5).
3.2. Effect of Stx2 on Fetal Status at 10 Days after Injection.
The number of fetoplacental resorptions in rats injected with
0.5 ng Stx2/g bwt was significantly higher than that observed
in control rats (Table 1). There was also a significantly higher
fetoplacental resorption in rats injected with 0.25 ng Stx2/g
bwt compared with controls.
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Figure 1: Evaluation of body weight and food and water intake. Time course of food intake (a), body weight (b), and water intake (c) of
pregnant rats i.p. injected with PBS (Ctrl, -e-), 0.25 ng Stx2/g bwt (-X-), or 0.5 ng Stx2/g bwt (-◼-). Each point of the curves represents the
mean ± SEM. In (a) and (b), ∗𝑃 < 0.05 for 0.25 (𝑛 = 8) and 0.5 ng Stx2/g bwt (𝑛 = 8) versus Ctrl (𝑛 = 8). In (c), there was no significant
difference between groups.
3.3. Structural Alterations in the Uteroplacental Unit. Struc-
tural alterations in the uteroplacental unit were analyzed
at 2, 4, and 6 days after injection. No differences were
observed at 2 days after injection (Figure 2(d)) with respect
to controls (Figure 2(a)). Growth restriction and hemorrhage
were observed in uteroplacental units injected with 0.5 ng/g
bwt at 4 days after injection (Figure 2(e)) and fetal resorp-
tions were observed at 6 days after injection (Figure 2(f))
compared with controls (Figures 2(b) and 2(c), resp.).
Macroscopical alterations were observed with 0.25 ng/g bwt
dose but with less damage compared with the other dose
(data not shown).
For histological evaluation, uteroplacental units were
collected at 4 and 6 days after injection of rats with 0.5 ng
Stx2/g bwt. Alterations in the placental histoarchitecture
with isolated haemorrhage (Figure 3(b)), necrotic areas, and
trophoblast fragmented nuclei (Figure 3(d)) were observed
in Stx2-treated rats compared with controls (Figures 3(a)
and 3(c), resp.). Leukocyte infiltration in decidua was also
observed in Stx2-treated rats (Figure 4(b)), but it was absent
in control rats deciduas (Figure 4(a)).
3.4. Detection of Gb3 and Stx2 in Decidua Tissues. To deter-
mine if Gb3 (Stx2 receptor) is present in the uteroplacental
unit, decidua and uterus tissues from normal rats at gd 8 were
subjected to lipid extraction followed by TLC (Figure 5(a)).
Two bands located at the same distance of Gb3 standard
revealed the presence of Gb3 in decidua and embryo cells but
not in the rat uterus. Furthermore, Stx2was immunolocalized
in the microvasculature and decidua cells of Stx2-treated rats
at 6 h after injection (Figure 5(b)). There was no staining in
decidua from control rats (Figure 5(c)).
3.5. Structural and Functional Alterations in Maternal Kid-
neys. To further analyze histological changes in kidneys
due to Stx2, renal tissues from pregnant rats treated with
0.5 ng Stx2/g bwt at 6 days after injection were processed
and stained with H&E. Glomerular epithelial adherences
and tubular necrosis were detected, by light microscopy,
in Stx2-treated rats (Figure 6(d)) compared with controls
(Figure 6(c)). Stx2 was detected by immunohistochemical
staining in glomerular and tubular cells at a short time of
6 h after injection (Figure 6(b)). No staining was detected in













Figure 2: Gross evaluation of pregnant uterus. Pregnant rats were injected with PBS or 0.5 ng Stx2/g bwt at different times. No differences
were observed at 2 days after injection (d) compared to control (a). Growth restriction and hemorrhage were observed in uteroplacental units
injected with 0.5 ng Stx2/g bwt at 4 days after injection (asterisk (e)), and fetal resorptions were observed at 6 days after injection (black arrows
(f)) compared with controls ((b) and (c), resp.).
Table 2: Plasma creatinine in Stx2-treated rats.
Stx2 dose Numberof rats
Plasma creatinine, mg/dL; days after Stx2
injection
2 4 6
Control 8 0.53 ± 0.03 0.48 ± 0.03 0.53 ± 0.05
0.25 ng/g bwt 5 0.65 ± 0.12 0.65 ± 0.11 0.55 ± 0.05
0.5 ng/g bwt 6 0.63 ± 0.03 0.81 ± 0.14∗ 0.85 ± 0.15∗
∗
𝑃 < 0.05 versus control.
control renal tissues (Figure 6(a)). Furthermore, a moderate
increase in creatinine plasma concentration (mg/dL) was
observed in rats treated with 0.5 ng Stx2/g bwt at 4 days
and 6 days after injection compared with controls (Table 2).
In contrast, no significant changes in creatinine plasma
concentration were detected in rats treated with 0.25 ng
Stx2/g bwt. In addition, at 2 days after injection, there were
no differences in creatinine concentrations with both doses
compared to controls (Table 2).
4. Discussion
In this study, we have evaluated the effects of sublethal
Stx2 doses on maternal and fetal status in the early postim-
plantation stage of pregnancy (gd 8). An i.p. injection of
0.25 and 0.5 ng/g bwt of Stx2 caused maternal damages and
pregnancy loss. Maternal infections have been described as
cause of spontaneous abortion and perinatal complications.
We propose the possibility that high circulation of STEC
strains could trigger pregnancy complications due to the
release of virulence factors like Stx2 in symptomatic or
asymptomatic STEC infections. Although a case of neonatal
HUS after mother-to-child transmission of STEC O157:H7
has been reported [6, 18, 23], up to date, no data is available
regarding loss of pregnancy linked to exposure to STEC in
humans.
We have previously reported that a combination of Stx2
and LPS i.p. injected in rats in the late stage of pregnancy
produces preterm delivery of dead fetuses [24]. We also
demonstrated that nitric oxide (NO) and tumor necrosis
factor (TNF-𝛼) play an important role in placental toxicity
and fetal mortality induced by Stx2 [24–26]. In addition, it
has been reported that STEC cause placentitis and abortion
in ewes [20].
In this study, we have demonstrated that sublethal Stx2
doses in the early stage of pregnancy induced maternal
weight loss and a decrease in food intake until 7 days after
injection. After that, rats gradually recovered, as shown in
several models of Stx2 injection [27], but did not reach the
appropriate weight for the corresponding day of pregnancy.
Moreover, our results indicated that Stx2 was localized in the
microvasculature and decidua cells where high levels of Gb3
were found. In agreement with our results, Yoshimura et al.
















Figure 3: Histological evaluation of the uteroplacental unit. Alterations in the histoarchitecture (black arrowheads (b)) and isolated focus
of hemorrhage (red arrow (b)) were observed in Stx2-treated rats. High magnification showed trophoblast fragmented nuclei (black arrows
(d)) and necrosis area (black asterisk (d)). Normal tissues were observed in control rats ((a) and (c)). Black squares in (a) and (b) indicate
the magnification zone corresponding to (c) and (d), respectively. (a, b): ×40; (c, d): ×200. D, decidua; G, trophoblast giant cells; L, labyrinth;
S, spongious layer.
(a) (b)
Figure 4: Leukocyte infiltration in decidua. Leukocyte infiltration in decidua tissues from the Stx2-treated rats (0.5 ng/g bwt) was observed
at 4 days after injection (black arrows (b)). Decidua tissues from control rats did not show leukocyte infiltration (a).
[28] reported that Stx2 induces fetoplacental resorption in
mice in the early stage of pregnancy [28]. These authors also
found that Stx2 injures the trophoblasts, causing intrauterine
hemorrhage, fibrin deposition, and neutrophil infiltration.
In accordance with this, our experiments demonstrated
significant morphological and histological damages in the
uteroplacental units and fetomaternal resorptions at 6–10
days after injection of Stx2. We have detected leukocyte
infiltration in decidua from Stx2-treated rats, which could be
the result of transmigration from the bloodmicrovasculature
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Figure 5: Detection of Gb3 and Stx2 in decidua tissues. Gb3 was detected in decidua tissues from normal pregnant rats at day 8 of gestation
by TLC ((a), line 1: standard of Gb3; line 2: decidual and embryo cells; line 3: uterus; line 4: complete site of implantation including uterus
decidua and embryo cells). Stx2 was detected in the microvasculature and decidua cells of the uteroplacental unit at 6 h after injection with
0.5 ng Stx2/g bwt (b). No staining was detected in control tissue (c). (b, c): ×400.
(a) (b)
(c) (d)
Figure 6: Stx2 localization in maternal kidney and histological evaluation. Stx2 was detected in glomerular and tubular cells of 0.5 ng Stx2/g
bwt treated rats at 6 h after injection by immunohistochemistry (b).This assay was repeated at least twice. No staining was detected in control
renal tissues (a). Glomerular epithelial adherences (black arrowhead) and tubular necrosis (black arrows) were observed in Stx2-treated rats
at 6 days after injection (d) compared with the controls (c). (a, b): ×400; (c, d): ×200.
to decidua tissues due to endothelial damages caused by Stx2
[29].
In this study, we have found histological and physio-
logical renal alterations in pregnant rats depending on the
Stx2 dose. It is known that kidneys develop physiological
adaptations to transition through gestation [30] and therefore
the combination of kidney disease and pregnancy could be a
high-risk situation in humans [31]. However, a 5/6 reduction
of renal mass in pregnant rats does not alter glomerular
hemodynamic responses to pregnancy [32]. Furthermore, in
the data presented here, loss of pregnancy at 0.25 ng Stx2/g
bwt without functional kidney alterations was observed.
Therefore, the possibility that maternal renal damages con-
tribute to Stx2-pregnancy loss is unlikely.
In conclusion, we propose that the detrimental effects on
pregnancy are related to the direct cytotoxic effects of Stx2
in the highly blood perfused uteroplacental unit. It is well
known that Stx2 affects the endothelium of microvasculature
[14, 33], and, in this work, we found Stx2 binding the
microvasculature of the uteroplacental unit. Our data suggest
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that these Stx2 cytotoxic effects could be responsible for
intrauterine growth restriction and final pregnancy loss.
Even though we cannot directly extrapolate our results to
the human placental response, it is tempting to propose that
Stx2 exposure during pregnancy could be investigated as one
of the causes of spontaneous miscarriage.
It is well known that rodents still possess significant
similarities with humans, in terms of reproductive biology
[34], so the fact that Stx2 causes pregnancy loss and preterm
delivery in rats may be an indication that this event could
happen in humans.
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